ContraFect

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.

OVERVIEW

Our therapeutic product candidates are direct lytic agents (DLAs) that represent a new, potential paradigm shift in the approach to treating bacterial infections, including those caused by drug-resistant pathogens.  Our focus is on achieving superior clinical outcomes for patients over current standard of care.

Drug resistance occurs when microbes such as bacteria and viruses change in ways that allow them to grow despite antibiotic and antiviral treatment. Overuse of antibiotics has contributed to dramatic increases in the prevalence of drug resistant bacteria, such as MRSA, which require longer and more expensive courses of treatment and are associated with substantial morbidity and mortality.

TECHNOLOGY

We leverage our lysin and amurin peptide platforms to develop innovative new therapies.